Maria Garcia-Cremades

Dr. Maria Garcia-Cremades

Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, CP 28040 Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NWNicholas D. Walter
Nicholas D. Walter
SBSarah E. M. Born
Sarah E. M. Born
GRGregory T. Robertson
Gregory T. Robertson
MRMatthew Reichlen
Matthew Reichlen
CDChristian Dide-Agossou
Christian Dide-Agossou
MVMartin I. Voskuil
Martin I. Voskuil
There is urgent need for new drug regimens that more rapidly cure tuberculosis (TB). Existing TB drugs and regimens vary in treatment-shortening activity, but the molecular basis of these differences is unclear, and no existing assay directly quantifies the ability of a drug or regimen to shorten treatment. Here, we show that drugs historically classified as sterilizing and non-sterilizing have distinct impacts on a fundamental aspect of Mycobacterium tuberculosis physiology: ribosomal RNA (rRNA) synthesis. In culture, in mice, and in human studies, measurement of precursor rRNA reveals that sterilizing drugs and highly effective drug regimens profoundly suppress M. tuberculosis rRNA synthesis, whereas non-sterilizing drugs and weaker regimens do not. The rRNA synthesis ratio provides a readout of drug effect that is orthogonal to traditional measures of bacterial burden. We propose that this metric of drug activity may accelerate the development of shorter TB regimens.

30 April 2019 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AGAnthony J. Garcia-Prats
Anthony J. Garcia-Prats
HSH. Simon Schaaf
H. Simon Schaaf
HDHeather R. Draper
Heather R. Draper
Maria Garcia-CremadesMaria Garcia-Cremades
Maria Garcia-Cremades
JWJana Winckler
Jana Winckler
RSRada Savic
Rada Savic
Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-TB) treatment. However, among children with MDR-TB, there are no linezolid pharmacokinetic data, and its adverse effects have not yet been prospectively described. We characterised the pharmacokinetics, safety, and optimal dose of linezolid in children treated for MDR-TB. Children routinely treated for MDR-TB in 2 observational studies (2011–2015, 2016–2018) conducted at a single site in Cape Town, South Africa, underwent intensive pharmacokinetic sampling after either a single dose or multiple doses of linezolid (at steady state). Linezolid pharmacokinetic parameters, and their relationships with covariates of interest, were described using nonlinear mixed-effects modelling. Children receiving long-term linezolid as a component of their routine treatment had regular clinical and laboratory monitoring. Adverse events were assessed for severity and attribution to linezolid. The final population pharmacokinetic model was used to derive optimal weight-banded doses resulting in exposures in children approximating those in adults receiving once-daily linezolid 600 mg. Forty-eight children were included (mean age 5.9 years; range 0.6 to 15.3); 31 received a single dose of linezolid, and 17 received multiple doses. The final pharmacokinetic model consisted of a one-compartment model characterised by clearance (CL) and volume (V) parameters that included allometric scaling to account for weight; no other evaluated covariates contributed to the model. Linezolid exposures in this population were higher compared to exposures in adults who had received a 600 mg once-daily dose. Consequently simulated, weight-banded once-daily optimal doses for children were lower than those currently used for most weight bands. Ten of 17 children who were followed long term had a linezolid-related adverse event, including 5 with a grade 3 or 4 event, all anaemia. Adverse events resulted in linezolid dose reductions in 4, temporary interruptions in 5, and permanent discontinuation in 4 children. Limitations of the study include the lack of very young children (none below 6 months of age), the limited number who were HIV infected, and the modest number of children contributing to long-term safety data. Linezolid-related adverse effects were frequent and occasionally severe. Careful linezolid safety monitoring is required. Compared to doses currently used in children in many settings for MDR-TB treatment, lower doses may approximate current adult target exposures, might result in fewer adverse events, and should therefore be evaluated.

19 April 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
CDChristian Dide-Agossou
Christian Dide-Agossou
ABAllison A. Bauman
Allison A. Bauman
MRMichelle E. Ramey
Michelle E. Ramey
KRKaren Rossmassler
Karen Rossmassler
RMReem Al Mubarak
Reem Al Mubarak
NWNicholas D. Walter
Nicholas D. Walter
Murine tuberculosis drug efficacy studies have historically monitored bacterial burden based on CFU of Mycobacterium tuberculosis in lung homogenate. In an alternative approach, a recently described molecular pharmacodynamic marker called the RS ratio quantifies drug effect on a fundamental cellular process, ongoing rRNA synthesis.

26 April 2022 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Maria Garcia-CremadesMaria Garcia-Cremades
Maria Garcia-Cremades
Katarina M VučićevićKatarina M Vučićević
Katarina M Vučićević
CHCraig W Hendrix
Craig W Hendrix
PJPriya Jayachandran
Priya Jayachandran
LJLeah Jarlsberg
Leah Jarlsberg
RSRada Savic
Rada Savic
Background: Daily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent. The target protective plasma concentration of tenofovir (TFV), however, is not fully understood. The aim of this study is to estimate the protective TFV plasma concentration.Methods: Participant data from TFV-based daily oral and topical active arms of phase 3 trials (iPrEx, VOICE, and Partners PrEP) were pooled (n = 2950). Individual specific risk scores (low and high risk) of acquiring HIV, based on an earlier placebo analysis, were created. Longitudinal TFV pharmacokinetics (PK), HIV outcome, individual risk scores and the effect of sex at birth data were integrated and analyzed using non-linear mixed effects models.Results: Around 50% of the individuals were estimated to be adherent, which differed from self-reported adherence (∼90%) and large variation between longitudinal adherence patterns were identified. Following oral administration, the estimated protective TFV trough concentration was substantially higher in high-risk females (45.8 ng/mL) compared with high-risk males (16.1 ng/mL) and to low-risk individuals (∼7.5 ng/mL). Dosing simulations indicated that high-risk women require full adherence to maintain protective levels.Conclusions: Using the largest PK-HIV outcome database to date, we developed a population adherence-PK-risk-outcome model. Our results indicate that high-risk females need higher levels of plasma TFV to achieve HIV protection compared with males. HIV protection exceeds 90% in all populations if daily adherence is achieved.

1 May 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
BVBianca Vora
Bianca Vora
DBDeanna J. Brackman
Deanna J. Brackman
LZLing Zou
Ling Zou
Maria Garcia-CremadesMaria Garcia-Cremades
Maria Garcia-Cremades
MSMarina Sirota
Marina Sirota
KGKathleen M. Giacomini
Kathleen M. Giacomini
The missense variant, breast cancer resistance protein (BCRP) p.Q141K, which encodes a reduced function BCRP, has been linked to poor response to allopurinol. Using a multifaceted approach, we aimed to characterize the relationship(s) between BCRP p.Q141K, the pharmacokinetics (PK) and pharmacodynamics (PD) of oxypurinol (the active metabolite of allopurinol), and serum uric acid (SUA) levels. A prospective clinical study (NCT02956278) was conducted in which healthy volunteers were given a single oral dose of 300 mg allopurinol followed by intensive blood sampling. Data were analyzed using noncompartmental analysis and population PK/PD modeling. Additionally, electronic health records were analyzed to investigate whether clinical inhibitors of BCRP phenocopied the effects of the p.Q141K variant with respect to SUA. Subjects homozygous for p.Q141K had a longer half‐life (34.2 ± 12.2 h vs. 19.1 ± 1.42 h) of oxypurinol. The PK/PD model showed that women had a 24.8% lower volume of distribution. Baseline SUA was affected by p.Q141K genotype and renal function; that is, it changed by 48.8% for every 1 mg/dl difference in serum creatinine. Real‐world data analyses showed that patients prescribed clinical inhibitors of BCRP have higher SUA levels than those that have not been prescribed inhibitors of BCRP, consistent with the idea that BCRP inhibitors phenocopy the effects of p.Q141K on uric acid levels. This study identified important covariates of oxypurinol PK/PD that could affect its efficacy for the treatment of gout as well as a potential side effect of BCRP inhibitors on increasing uric acid levels, which has not been described previously.

1 March 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Maria Garcia-CremadesMaria Garcia-Cremades
Maria Garcia-Cremades
CPCeline Pitou
Celine Pitou
PIPhilip W. Iversen
Philip W. Iversen
José Ignacio de TrocónizJosé Ignacio de Trocóniz
José Ignacio de Trocóniz